Niclosamide inhibits TGF-β1-induced fibrosis of human Tenon's fibroblasts by regulating the MAPK-ERK1/2 pathway
Experimental Eye Research · 2023
DOI: 10.1016/j.exer.2023.109628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Eye Research, 2023. Verfasst von Liyun Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jinzhou Medical University, Jinzhou, 121001, Liaoning, China. Hauptthemen laut MEDLINE: Glaucoma, Niclosamide, Transforming Growth Factor beta1. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Iran Nanotechnology Initiative Council, Sanming Project of Medicine in Shenzen Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Preventing postoperative bleb scar formation is an effective way of improving glaucoma filtration surgery (GFS) outcome. Use of more effective antifibrotic drugs with fewer adverse effects may be a good way to address the problem. In the present study, we use a primary cell model, consisting of Tenon's fibroblasts obtained from patients with glaucoma, which were stimulated with TGF-β1 to induce the fibrotic phenotype. We explored the effects of niclosamide on TGF-β1-induced fibrosis in these cells and examined its underlying mechanism of action. A transcriptome sequencing assay was used to explore possible signaling pathways involved. Niclosamide inhibited cell proliferation and migration, and decreased the levels of alpha-smooth muscle actin, type I and type III collagen in human Tenon's fibroblasts induced by TGF-β1. Niclosamide also induced apoptosis and counteracted TGF-β1-induced cytoskeletal changes and extracellular matrix accumulation. Moreover, niclosamide decreased TGF-β1-induced phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2) protein expression in human Tenon's fibroblasts. The results indicate that niclosamide inhibits TGF-β1-induced fibrosis in human Tenon's fibroblasts by blocking the MAPK-ERK1/2 signaling pathway. Thus, niclosamide is a potentially promising antifibrotic drug that could improve glaucoma filtration surgery success rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jinzhou Medical University, Jinzhou, 121001, Liaoning, China.
- Department of Pediatric Respiratory Medicine, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430070, China.
- Shenzhen Eye Hospital, Jinan University, Shenzhen Eye Institute, Shenzhen, 518000, Guangdong, China.
- Shenzhen Eye Hospital, Jinan University, Shenzhen Eye Institute, Shenzhen, 518000, Guangdong, China. Electronic address: wangjiantao65@126.com.
Förderung
- Iran Nanotechnology Initiative Council
- Sanming Project of Medicine in Shenzen Municipality
- National Natural Science Foundation of China
Zitieren
APA
Zhang, L., Li, W., Liu, X., Guo, J., Wu, X., & Wang, J. (2023). Niclosamide inhibits TGF-β1-induced fibrosis of human Tenon's fibroblasts by regulating the MAPK-ERK1/2 pathway. Experimental Eye Research. https://doi.org/10.1016/j.exer.2023.109628
Vancouver
Zhang L, Li W, Liu X, Guo J, Wu X, Wang J. Niclosamide inhibits TGF-β1-induced fibrosis of human Tenon's fibroblasts by regulating the MAPK-ERK1/2 pathway. Experimental Eye Research. 2023. doi:10.1016/j.exer.2023.109628
BibTeX
@article{Zhang2023,
author = {Zhang, Liyun and Li, Wei and Liu, Xin and Guo, Junhong and Wu, Xueping and Wang, Jiantao},
title = {Niclosamide inhibits TGF-β1-induced fibrosis of human Tenon's fibroblasts by regulating the MAPK-ERK1/2 pathway},
journal = {Experimental Eye Research},
year = {2023},
doi = {10.1016/j.exer.2023.109628}
}
EUVIMED